We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Enovis
ENOV
$1.78B
| $218K | 0.03% |
+4,134
| New | +$241K |
|
552
Ferguson
FERG
$49.6B
| $217K | 0.03% |
+1,321
| New | +$209K |
|
553
Fidelity National Financial
FNF
$13.9B
| $216K | 0.03% |
+5,235
| New | +$210K |
|
554
Phillips 66
PSX
$82.5B
| $216K | 0.03% |
1,799
-19,275
| -91% | -$2.16M |
|
555
MGIC Investment
MTG
$6.35B
| $215K | 0.03% |
+12,869
| New | +$219K |
|
556
BCE
BCE
$20.5B
| $213K | 0.02% |
+5,585
| New | +$235K |
|
|
X
557
DELISTED
US Steel
X
| $213K | 0.02% |
6,563
-14,134
| -68% | -$396K |
|
558
Curtiss-Wright
CW
$28B
| $212K | 0.02% |
+1,082
| New | +$214K |
|
559
Arch Capital
ACGL
$33.9B
| $209K | 0.02% |
+2,616
| New | +$204K |
|
560
Sprinklr
CXM
$1.56B
| $205K | 0.02% |
+14,826
| New | +$212K |
|
561
Edison International
EIX
$27.2B
| $201K | 0.02% |
+3,179
| New | +$221K |
|
562
Under Armour
UAA
$2.92B
| $194K | 0.02% |
28,334
-1,899
| -6% | -$14.3K |
|
563
Snap
SNAP
$9.74B
| $194K | 0.02% |
21,780
-163,410
| -88% | -$1.71M |
|
564
Organon & Co
OGN
$3.56B
| $175K | 0.02% |
10,056
-11,045
| -52% | -$230K |
|
565
Maravai LifeSciences
MRVI
$948M
| $172K | 0.02% |
+17,187
| New | +$189K |
|
566
Gold Fields
GFI
$30.5B
| $165K | 0.02% |
+15,159
| New | +$200K |
|
|
AGNT
567
AGNT Inc
AGNT
$693M
| $164K | 0.02% |
+10,128
| New | +$209K |
|
568
Barclays
BCS
$94.5B
| $143K | 0.02% |
18,361
+8,281
| +82% | +$64.3K |
|
569
Robinhood
HOOD
$84.1B
| $131K | 0.02% |
+13,395
| New | +$149K |
|
570
Lyft
LYFT
$6.35B
| $129K | 0.02% |
+12,206
| New | +$136K |
|
571
Haleon
HLN
$43.1B
| $110K | 0.01% |
13,265
+3,218
| +32% | +$26.8K |
|
572
Genworth Financial
GNW
$3.76B
| $93.7K | 0.01% |
+15,985
| New | +$92.3K |
|
573
Sally Beauty Holdings
SBH
$1.58B
| $91.3K | 0.01% |
10,898
-27,254
| -71% | -$289K |
|
574
Cushman & Wakefield Ltd
CWK
$3.3B
| $86.8K | 0.01% |
11,389
-62,023
| -84% | -$561K |
|
|
RDFN
575
DELISTED
Redfin
RDFN
| $86.5K | 0.01% |
+12,280
| New | +$135K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.